Tissue factor (TF) and urokinase plasminogen activator receptor (uPAR) and bleeding complications in leukemic patients

Thrombosis and Haemostasis

Volumn 77, Issue 1, 1997, Pages 62-70

  López Pedrera, Chary ^a   Jardí, Merce ^a   Malagón, Maria Del Mar ^a   Inglés Esteve, Julia ^b   Dorado, Gabriel ^a   Torres, Antonio ^a   Félez, Jordi ^b   Velasco, Francisco ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; MESSENGER RNA; THROMBOPLASTIN; UROKINASE;

ARTICLE; BLAST CELL; BLEEDING; BLOOD CLOTTING; CELL LINE; CELL LYSATE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; LEUKEMIA; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; RELIABILITY;

EID: 1642393975     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655908     Document Type: Article

References (69)

1. Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 8: 385-90.
2. Mackman N. Regulation of the Tissue Factor Gene. FASEB J 1995; 9: (10) 883-9.
3. Carmeliet P, Mackman N, Wyns S, Kieckens L, Edgington TS, Collen D. Inactivation of the tissue factor gene in embryonic stem cells. Thromb Haemost 1995; 73: 1177 (1059, Abstract).
4. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97.
5. Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109: 389-95.
6. Drake TA, Cheng J, Chang A, Taylor FB, Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142: 1458-70.
7. Flössel C, Luther T, Müller M, Albrecht S, Kasper M. Immunohistochemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue. Histochemistry 1994; 101: 449-53.
8. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206-10.
9. Del Prete G, De Carli M, Lammel RM, D'Elios MM, Daniel KC, Giusti B, Abbate R, Romagnani S. Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood 1995; 86: 250-7.
10. Callander NS, Varki N, Mohan Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70: 1194-201.
11. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992; 11: 249-66.
12. Silverstein RL, Nachman RL. Cancer and clotting - Trousseau's warning. N Engl J Med 1992; 327: 1163-4.
13. Prandoni P, Lensing AWA, Büller HR. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. The New England Journal of Medicine 1992; 327: 1128-33.
14. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-6.
15. Tallman MS, Hakimian D, Kwann HC, Rickles FR. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. Leukemia and Lymphoma 1993; 11: 27-36.
16. Grignani F, Fagioli M, Alcalay M, Longo L, Donti E, Biondi A, LoCoco F, Pelicci G. Acute promyelocytic leukemia: From genetics to treatment. Blood 1994; 83: 10-25.
17. Hair GA, Padula S, Zeff R, Schmeizl M, Contrino J, Kreutzer DL, De Moerloose P, Boyds AW, Stanley I, Burgess AW, Rickles FR. Tissue Factor Expression in Human Leukemic Cells. Leukemia Res 1996; 20: (1)1-11.
18. Takahashi H, Satoh N, Wada K, Takakuwa E, Seki Y, Shibata A. Tissue factor in plasma of patients with disseminated intravascular coagulation. Am J Hematol 1994; 46: 333-7.
19. Wada H, Nakase T, Nakaya R, Minamikawa K, Wakita Y, Kaneko T, Ohiwa M, Deguchi K, Shirakawa S. Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation. Am J Hematol 1994; 45: 232-6.
20. Iijima K, Fukuda C, Nakamura K. Measurements of tissue factor-like activity in plasma of patients with DIC. Thromb Res 1991; 61: 29-38.
21. Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, Kuriyama R, Matsuzawa K, Hasegawa R, Aoki N. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994; 87: 343-7.
22. Andoh K, Kubota T, Takada M, Tanaka H, Kobayashi N, Mackawa T. Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. Cancer 1987; 59: 748-54.
23. Velasco F, Torres A, Rojas R, Alvarez MA, Gomez P, Castillo D. Increase in the D-Dimer levels during treatment in patients with acute myelogenous leukemia. Haemostasis 1992; 22: 117-23.
24. García Frade LJ, Sureda A, Torrado MC, García Avello A. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia. Acta Haematol 1992; 88: 7-10.
25. Tapiovaara H, Stephens RW, Vahteri A. Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells in vitro. Int J Cancer 1993; 53: 499-505.
26. Gruneiro AJ, Montesanti DP, Corasanti JG, Markus G. The induction of the plasminogen activator system during phorbol ester (PMA)-induced differentiation in HL-60 leukemic cells. Fibrinolysis 1995; 9: 71-8.
27. Plesner T, Ralfkiær E, Wittrup M, Johnsen H, Pyke C, Pedersen Hansen NE, Dano K. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 1994; 102: 835-41.
28. Plesner T, Ploug M, Ellis V, Ronne E, Hoyer-Hansen G, Wittrup M, Lindhardt Pedersen T, Tscherning T, Dano K, Hansen NE. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994; 83: 808-15.
29. Nykjær A, Moller B, Todd RF, III, Christensen T, Andreasen PA, Gliemann J, Petersen CM. Urokinase receptor: An activation antigen in human T lymphocytes. J Immunol 1994; 152: 505-16.
30. Jardí M, Inglés-Esteve J, Fabregas P, Félez J. Different expression of urokinase receptors (uPAR) among leukemic cells. Thromb Haemost 1993; 69: 608 (231, Abstract).
31. Vassalli J. The urokinase receptor. Fibrinolysis 1994; 8: 172-81.
32. Blasi F, Conese M, Moller LB, Pedersen N, Cavallaro U, Cubellis MV, Fazioli F, Hernandez-Marrero L, Limongi P, Munoz-Canoves P, Resnati M, Riitinen L, Sidenius N, Soravia E, Soria MR, Stoppelli MP, Talarico D, Teesalu T, Valcamonica S. The Urokinase Receptor: Structure, Regulation and Inhibitor-mediated Internalization. Fibrinolysis 1994; 8: 182-8.
33. Danø K, Behrendt N, Brunner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8: 189-203.
34. Conese M, Blasi F. Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation. Biol Chem Hoppe Seyler 1995; 376: 143-55.
35. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266; 12752-8.
36. Ellis V, Pyke C, Eriksen J, Solberg H, Danø K. The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion. Ann NY Acad Sci 1992; 667: 13-31.
37. Bennett JM, Catovsky D, Daniel MT. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 626-9.
38. Velasco F, Torres A, Andres P, Martinez F, Gomez P. Changes in plasma levels of protease and fibrinolytic inhibitors induced by treatment in acute myeloid leukemia. Thromb Haemost 1984; 52: (1) 81-4.
39. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
40. Granelli-Piperno A, Vassalli J, Reich E. Secretion of plasminogen activator by human polymorphonuclear leukocytes. J Exp Med 1989; 146: 1693-705.
41. Carson S. Continous chromogenic tissue factor assay comparison to clot-based assays and sensitivity established using pure tissue factor. Br J Haematol 1987; 47: 379-87.
42. Haire WD, Pirruccello SJ, Carson SD. Monocyte tissue factor in treated Hodgkin's disease. Leuk Lymphoma 1994; 12: 259-63.
43. Kubota T, Andoh K, Sadakata H, Tanaka H, Kobayashi N. Tissue Factor Released from Leukemic Cells. Thromb Haemost 1991; 65: 59-63.
44. Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G. Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res 1989; 56: 425-30.
45. Carson SD, Pirrucello SJ, Haire WD. Tissue factor antigen and activity are not expressed on the surface of intact cells isolated from an acute promyelocytic leukemia patient. Thromb Res 1990; 59: 159-70.
46. Tanaka M, Yamanishi H. The expression of tissue factor antigen and activity on the surface of leukemic cells. Leuk Res 1993; 17: 103-11.
47. Dickinson JL, Antalis TM. Tissue factor and plasminogen activator inhibitor expression in the differentiation of myeloid leukemic cells. Leukemia 1993; 7: (6) 864-71.
48. Rickles FR, Hair GA, Zeff RA, Lee E, Bona RD. Tissue factor expression in human leukocytes and tumor cells. Thromb Haemost 1995; 74: (1) 391-5.
49. Parry GCN, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb 1995; 15: 612-21.
50. Jardí M, Inglés-Esteve J, Burgal M, Azqueta C, Velasco F, Miles LA, Félez J. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Thromb Haemost 1996; 76: 1009-19.
51. Claxton DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson BS, Estev E, Cork A, Huh YO, Trujillo J, Deisseroth AB. Correlation of CD2 Expression with PML Gene Breakpoints in patients with acute promyelocytic leukemia. Blood 1992; 80: 582-6.
52. Van der Logt CPE, Reitsma PH, Bertina RM. Alternative splicing is responsible for the presence of two tissue factor mRNA species in LPS stimulated human monocytes. Thromb Haemost 1992; 67: 272-6.
53. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
54. Mohri M, Oka M, Aoki Y, Gonda Y, Hirata S, Gomi K, Kiyoata T, Sugihara T, Yamamoto S, Ishida T, Maruyama I. Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats. Am J Hematol 1994; 45: 298-303.
55. Warr TA, Rao VM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic inhibitor activity. Blood 1990; 7: 1481-9.
56. Jang I-K, Gold HK, Leinbach RC, Fallon JT, Collen D, Wilcox JN. Antitnrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler Thromb 1992; 12: 948-54.
57. Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77: 1949-57.
58. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. J Biol Chem 1989; 264: 2185-8.
59. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-8.
60. Plow EF, Felez J, Miles LA. Cellular Regulation of Fibrinolysis. Thromb Haemost 1991; 66: 32-6.
61. Ploug M, Eriksen J, Plesner T, Hansen NE, Danø K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem 1992; 208: 397-404.
62. Chapman HA, Stone OL. Characterization of a macrophage-derived plasminogen-activator inhibitor. Biochem J 1985; 230: 109-16.
63. Vassalli J, Dayer J, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653.
64. Hart PH, Burgess DR, Vitti GF, Hamilton JA. Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood 1989; 74: 1222-5.
65. Hart PH, Vitti GF, Burgess DR. Singleton DK, Hamilton JA. Human monocytes can produce tissue-type plasminogen activator. J Exp Med 1989; 169: 1509-14.
66. Broze GJ, Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
67. Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1988; 71: (4)870-5.
68. Cozzolino F, Torcia M, Miliani A, Carossino AM, Giordani R, Cinotti S, Filimberti E, Saccardi R, Bernabei P, Guidi G, Di Guglielmo R, Pistoia V, Ferrarini M, Nawroth PP, Stern D. Potential role of interleukine-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. The American Journal of Medicine 1988; 84: 240-50.
69. Cozzolino F, Rubartelli A, Aldinucci D, Sitia R, Torcia M, Shaw A, Di Guglielmo R. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci USA 1989; 86: 2369-73.